Business intelligence reports for the lab diagnostics industry
Subscribe for Exclusive Access.
Subscriptions & Reports
![Mar2022-DTET-Cover](https://g2woo.wpengine.com/wp-content/uploads/2022/03/Mar2022-DTET-Cover.webp)
![March2022-LCA.Cover](https://g2woo.wpengine.com/wp-content/uploads/2022/03/March2022-LCA.Cover_.webp)
![March2022-LIR-Cover](https://g2woo.wpengine.com/wp-content/uploads/2022/03/March2022-LIR-Cover.webp)
![April-2022-NLR-Briefing-Cover](https://g2woo.wpengine.com/wp-content/uploads/2022/03/April-2022-NLR-Briefing-Cover.webp)
Interested in multiple copies or more than one of our G2 reports?
Call Sokha at 855-528-6903 or email spearson@g2intelligence.com to discuss pricing.
No Results Found
The posts you requested could not be found. Try changing your module settings or create some new posts.
No Results Found
The posts you requested could not be found. Try changing your module settings or create some new posts.
No Results Found
The posts you requested could not be found. Try changing your module settings or create some new posts.
FDA Orders LuSys and Celltrion to Recall Unauthorized COVID-19 Rapid Tests
This week, two companies announced Class I recalls, the most serious kind, for COVID-19 antigen and antibody tests that have reached the US market without FDA Emergency Use Authorization (EUA) or 510(k) clearance. San Diego-based LuSys Laboratories is recalling...
How CSF Tests May Help Recruitment for Alzheimer’s Drug Clinical Trials
A recent study shows these tests may make it easier and more cost-effective to identify patients for studies of new PET treatments.
After Steady Decline, Telehealth Use Surges during Omicron
When the pandemic and lockouts first began, telehealth utilization soared to unprecedented levels. But while telehealth use remains well above pre-pandemic levels, thanks in part to relaxed Medicare coverage rules, the initial wave steadily ebbed starting in May...
FDA Grants Approval to Breast Cancer Treatment and Companion Diagnostic
Certain cancer patients now have access to a new treatment option and companion diagnostic. On March 11, the U.S. Food and Drug Administration approved olaparib (Lynparza, AstraZeneca Pharmaceuticals, LP) for treating adults with deleterious or suspected...
US Government Launches Nationwide Test-to-Treat Initiative
Recently unveiled program aims to ensure easy access to COVID-19 treatments for all eligible Americans.
Physicians Get a Break on 2021 MIPS Payment Adjustments
Just as it seemed like physician practice patterns were getting back to normal, the late-year Omicron surge skewed the Merit-based Incentive Payment System (MIPS) quality data for 2021. With that in mind, the Centers for Medicare & Medicaid Services (CMS) has...
Potential New Test Could Diagnose Lyme Disease Sooner
For scientists and clinicians alike, one of the Holy Grails for successfully treating and curing Lyme disease is developing tests that identify the disease sooner, show when people are cured of infection, and can diagnose reinfection. Now, researchers at Tufts...